Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J. Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy P. Hughes, Klaus Lechner, Johan Lanng Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John D. Shepherd, Bengt Simonsson, Aloïs Gratwohl, John M. Goldman, Hagop M. Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E. Bolton, Renaud Capdeville, Brian Druker

New England Journal of Medicine, 2003

Newcastle University, Centre Hospitalier Universitaire de Poitiers, University of Chicago, Novartis (Switzerland), Policlinico S.Orsola-Malpighi, Hospital Clínic de Barcelona, Erasmus MC Cancer Institute, Johannes Gutenberg University Mainz, Heidelberg University, Royal Adelaide Hospital, Hôpital Saint-Louis, Centre Hospitalier Universitaire de Bordeaux, Ospedale San Luigi Gonzaga, Vancouver General Hospital, Uppsala University Hospital, Kantonsspital Baselland, Hammersmith Hospital, The University of Texas MD Anderson Cancer Center, Mater Misericordiae Hospital, Universitair Ziekenhuis Leuven, Oregon Health & Science University

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

3551

Citations

View on Google Scholar

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Abstract

Journal Details

Join JournalsHub

Welcome Back